Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510214-11-00

Acronym

ISM-GBM

Enrollment

Registered

2024-10-22

Start date

2023-03-21

Completion date

Unknown

Last updated

2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Glioblastoma

Brief summary

Ability to perform drug-screen and select possible treatment strategy

Detailed description

Tumor volume ccording to response assessment in neuro-oncology (RANO) criteria, Adverse events induced by selected treatments, Overall survival in treated patients, Comparsion of drug response to individual molecular fingerprint of drug selectivity.

Interventions

DRUGGemcitabine Accord 100 mg/ml konsentrat til infusjonsvæske

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Ability to perform drug-screen and select possible treatment strategy	—

Secondary

Measure	Time frame
Tumor volume ccording to response assessment in neuro-oncology (RANO) criteria, Adverse events induced by selected treatments, Overall survival in treated patients, Comparsion of drug response to individual molecular fingerprint of drug selectivity.	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026